The potential of proton beam radiation therapy in gastrointestinal cancer

References

• Cancer Incidence in Sweden. Epidemiologiskt Centrum 2003; www.sos.se.
   Google Scholar
• Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049–53
   PubMed Web of Science ®Google Scholar
• Albertsson M. Chemoradiotherapy of esophageal cancer. Acta Oncol 2002; 41: 118–23
   PubMed Web of Science ®Google Scholar
• Ask A, Albertsson M, Järhult J, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in oesophageal cancer. Acta Oncol 2003; 42: 462–75
   PubMed Web of Science ®Google Scholar
• Tai P, Van Dyk J, Yu E, Battista J, Stitt L, Coad T. Variability of target volume delineation in cervical esophageal cancer. Int J Radiat Oncol Biol Phys 1998; 42: 277–88
   PubMed Web of Science ®Google Scholar
• Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N, et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol 2004; 73: 269–75
   PubMed Web of Science ®Google Scholar
• Bedford JL, Viviers L, Guzel Z, Childs PJ, Webb S, Tait DM. A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Radiother Oncol 2000; 57: 183–93
   PubMedGoogle Scholar
• Nutting CM, Bedford JL, Cosgrove VP, Tait DM, Dearnaley DP, Webb S. A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol 2001; 61: 157–63
   PubMed Web of Science ®Google Scholar
• Wu VW, Sham JS, Kwong DL. Inverse planning in three-dimensional conformal and intensity-modulated radiotherapy of mid-thoracic oesophageal cancer. Br J Radiol 2004; 77: 568–72
   PubMed Web of Science ®Google Scholar
• Tait DM. Multi-modality treatment in oesophageal cancer: a curse for radiotherapy progress. Radiother Oncol 2004; 73: 115–7
   PubMedGoogle Scholar
• Okawa T, Dokiya T, Nishio M, Hishikawa Y, Morita K. Multi-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Int J Radiat Oncol Biol Phys 1999; 45: 623–8
   PubMedGoogle Scholar
• Koyama S, Tsujii H, Yokota H, Hotta S, Miyo Y, Fukutomi H, et al. Proton beam therapy for patients with esophageal carcinoma. Jpn J Clin Oncol 1994; 24: 144–53
   PubMed Web of Science ®Google Scholar
• Tsunemoto H, Ishikawa T, Morita S, Kitagawa T, Tsujii H. Indications of particle radiation therapy in the treatment of carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1992; 22: 321–4
   PubMed Web of Science ®Google Scholar
• Isacsson U, Lennernäs B, Grusell E, Jung B, Montelius A, Glimelius B. Comparative treatment planning between proton and x-ray therapy in esophageal cancer. Int J Radiat Oncol Biol Phys 1998; 41: 441–50
   PubMed Web of Science ®Google Scholar
• Graffman S, Jung B. Clinical trials in radiotherapy and the merits of high energy protons. Acta Radiol Ther Phys Biol 1970; 9: 1–23
   PubMedGoogle Scholar
• Möller TR, Brorsson B, Ceberg J, Frodin JE, Lindholm C, Nylen U, et al. A prospective survey of radiotherapy practice in Sweden. Acta Oncol ;42 2001; 2003: 387–410
   Google Scholar
• Talbäck M, Stenbeck M, Rosén M, Glimelius B. Cancer survival in Sweden. Acta Oncol 2003; 42: 637–59
   PubMed Web of Science ®Google Scholar
• Jansen EP, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005; 23: 4509–17
   PubMedGoogle Scholar
• Janunger K, Hafström Lo, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40: 309–26
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2005: Abstr 4001.
   Google Scholar
• MacDonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–30
   PubMed Web of Science ®Google Scholar
• Leong T, Willis D, Joon DL, Condron S, Hui A, Ngan SY. 3D conformal radiotherapy for gastric cancer–results of a comparative planning study. Radiother Oncol 2005; 74: 301–6
   PubMed Web of Science ®Google Scholar
• Glimelius B. Has progress been made in gastrointestinal cancer treatment?. Acta Oncol 2002; 41: 115–7
   PubMed Web of Science ®Google Scholar
• Smalley SR, Gunderson L, Tepper J, Martenson JA, Minsky BD, Willett C, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int J Radiat Oncol Biol Phys 2002; 52: 283–93
   PubMed Web of Science ®Google Scholar
• White RR, Tyler DS Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am 2004;13:675–84, ix–x.
   PubMedGoogle Scholar
• White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 2005; 12: 214–21
   PubMedGoogle Scholar
• Yamaguchi K, Nakamura K, Kobayashi K, Nakano K, Konomi H, Mizumoto K, et al. ERT following IORT improves survival of patients with resectable pancreatic cancer. Hepatogastroenterology 2005; 52: 1244–9
   PubMedGoogle Scholar
• Ihse I, Andersson R, Ask A, Ewers SB, Lindell G, Tranberg KG. Intraoperative radiotherapy for patients with carcinoma of the pancreas. Pancreatology 2005;5:438–43.
   PubMedGoogle Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576–85
   PubMed Web of Science ®Google Scholar
• Glimelius B. Pancreatic and hepatobiliary cancers: adjuvant therapy and management of inoperable disease. Ann Oncol 2000; 11: 153–9
   PubMedGoogle Scholar
• Wilkowski R, Thoma M, Weingandt H, Duhmke E, Heinemann V. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. JOP 2005; 6: 216–30
   PubMedGoogle Scholar
• Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000; 89: 314–27
   PubMed Web of Science ®Google Scholar
• Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol 2005; 23: 4538–44
   PubMed Web of Science ®Google Scholar
• Imamura M, Doi R, Imaizumi T, Funakoshi A, Wakasugi H, Sunamura M, et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 2004; 136: 1003–11
   PubMedGoogle Scholar
• Zurlo A, Lomax A, Hoess A, Bortfeld T, Russo M, Goitein G, et al. The role of proton therapy in the treatment of large irradiation volumes: a comparative planning study of pancreatic and biliary tumors. Int J Radiat Oncol Biol Phys 2000; 48: 277–88
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Hafström Lo, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282–308
   PubMed Web of Science ®Google Scholar
• Glimelius B. Palliative treatment of patients with colorectal cancer. Scand J Surg 2003; 92: 74–83
   PubMedGoogle Scholar
• Johnson PJ. Primary liver tumours. Oxford Textbook of Oncology2nd edn, RL Souhami IT, P Hohenberger, J-C Horiot. Oxford University Press, Oxford 2002; 1627–40
   Google Scholar
• Glimelius B. Liver metastases. Oxford Textbook of Oncology2nd edn, RL Souhamiit, P Hohenberger, J-C Horiot. Oxford University Press, Oxford 2002; 1663–80
   Google Scholar
• Ingold JA, Reed GS, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol 1965; 93: 200
   Web of Science ®Google Scholar
• Mohiuddin M, Chen E, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 1996; 14: 722–8
   PubMed Web of Science ®Google Scholar
• Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 150–5
   PubMed Web of Science ®Google Scholar
• Blomgren H, Lax I, Göranson H, Kræpelien T, Nilsson B, Näslund I, et al. Radiosurgery for tumors in the body: Clinical experience using a new method. J Radiosurg 1998; 1: 63–75
   Google Scholar
• Matsuzaki Y. The efficacy of powerful proton radiotherapy for hepatocellular carcinoma – Long term effects and QOL. Ann Cancer Res Ther 1998; 8: 9–17
   Google Scholar
• Matsuzaki Y, Osuga T, Saito Y, Chuganji Y, Tanaka N, Shoda J, et al. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994; 106: 1032–41
   PubMedGoogle Scholar
• Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005; 23: 1839–46
   PubMed Web of Science ®Google Scholar
• Tokuuye KYA, Hashimoto T, et al. Clinical results of proton radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003; 383: (abstr)
   Google Scholar
• Kato H, Tsujii H, Miyamoto T, Mizoe JE, Kamada T, Tsuji H, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004; 59: 1468–76
   PubMed Web of Science ®Google Scholar
• Glimelius B, Grönberg H, Järhult J, Wallgren A, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 476–92
   PubMed Web of Science ®Google Scholar
• Glimelius B. Balancing gains and costs in radiation therapy of rectal cancer. Dis Colon Rectum 2005; in press.
   Google Scholar
• Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005;.
   Google Scholar
• Marijnen CA, van de Velde CJ, Putter H, van den Brink M, Maas CP, Martijn H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847–58
   PubMed Web of Science ®Google Scholar
• Jansson-Frykholm G, Påhlman L, Glimelius B. Combined chemo- and radiotherapy vs radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2001; 50: 427–34
   PubMedGoogle Scholar
• Glimelius B. Chemoradiotherapy for rectal cancer-is there an optimal combination?. Ann Oncol 2001; 12: 1039–45
   PubMed Web of Science ®Google Scholar
• Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098–104
   PubMed Web of Science ®Google Scholar
• Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 665–77
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez JA, Calvo FA, Cortes J, de La Mata D, Gomez-Espi M, Lozano MA, et al. Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer. Int J Radiat Oncol Biol Phys 2005; 61: 1378–84
   PubMedGoogle Scholar
• Chapet O, Romestaing P, Mornex F, Souquet JC, Favrel V, Ardiet JM, et al. Preoperative radiotherapy for rectal adenocarcinoma: Which are strong prognostic factors?. Int J Radiat Oncol Biol Phys 2005; 61: 1371–7
   PubMedGoogle Scholar
• Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-Tiefenbacher U, Muldner A, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005; 23: 1350–7
   PubMed Web of Science ®Google Scholar
• Wiig JN, Poulsen JP, Tveit KM, Olsen DR, Giercksky KE. Intra-operative irradiation (IORT) for primary advanced and recurrent rectal cancer. a need for randomised studies. Eur J Cancer 2000; 36: 868–74
   PubMedGoogle Scholar
• Alektiar KM, Zelefsky MJ, Paty PB, Guillem J, Saltz LB, Cohen AM, et al. High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 2000; 48: 219–26
   PubMed Web of Science ®Google Scholar
• Frykholm-Jansson G, Isacsson U, Sintorn K, Montelius A, Jung B, Påhlman L, et al. Preoperative radiotherapy in rectal carcinoma-aspects of adverse effects and radiation technique. Int J Radiat Oncol Biol Phys 1996; 35: 1039–1048
   PubMedGoogle Scholar
• Duthoy W, De Gersem W, Vergote K, Boterberg T, Derie C, Smeets P, et al. Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. Int J Radiat Oncol Biol Phys 2004; 60: 794–806
   PubMed Web of Science ®Google Scholar
• Isacsson U, Montelius A, Jung B, Glimelius B. Comparative treatment planning between proton and x-ray therapy in locally advanced rectal cancer. Radiother Oncol 1996; 41: 263–272
   PubMed Web of Science ®Google Scholar
• Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H, et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol 2003; 42: 800–8
   PubMed Web of Science ®Google Scholar